Prediction of remission of depression with clinical variables, neuropsychological performance, and serotonergic/dopaminergic gene polymorphisms

Human Psychopharmacology

Volumn 27, Issue 6, 2012, Pages 577-586

  Gudayol Ferré, Esteve ^a   Herrera Guzmán, Ixchel ^a   Camarena, Beatriz ^f   Cortés Penagos, Carlos ^a   Herrera Abarca, Jorge E ^a   Martínez Medina, Patricia ^d   Asbun Bojalil, Juan ^c   Lira Islas, Yuridia ^b   Reyes Ponce, Celia ^b   Guàrdia Olmos, Joan ^e  

^a UNIVERSIDAD MICHOACANA DE SAN NICOLÁS DE HIDALGO   (Mexico)

^b Clínica de Enfermedades Crónicas y Procedimientos Especiales CECYPE Mich   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^d SECRETARÍA DE SALUD   (Mexico)

^e Institut de Recerca en Cervell   (Spain)

^f INSTITUTO NACIONAL DE PSIQUIATRÍA RAMÓN DE LA FUENTE MUÑIZ   (Mexico)

Author keywords

5HTTLPR; antidepressant response; COMT; major depressive disorder; neuropsychological assessment; polymorphism

Indexed keywords

CATECHOL METHYLTRANSFERASE; FLUOXETINE; SEROTONIN TRANSPORTER; SEROTONIN TRANSPORTER LINKED POLYMORPHIC REGION; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DEPRESSION; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; NEUROPSYCHOLOGY; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SENSITIVITY AND SPECIFICITY;

ADULT; ANTIDEPRESSIVE AGENTS; CATECHOL O-METHYLTRANSFERASE; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG RESISTANCE; FEMALE; FLUOXETINE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MEXICO; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; REMISSION INDUCTION; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 84868552801     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2267     Document Type: Article

References (64)

1. Airaksinen E, Larsson ML, Lundberg I, Forsell Y,. 2004. Cognitive functions in depressive disorders: evidence from a population based study. Psychol Med 34: 83-91.
2. Alexopoulos GS, Kiosses DN, Heo M, Murphy CF, Shanmugham B, Gunning-Dixon F,. 2005. Executive dysfunction and the course of geriatric depression. Biol Psychiatry 58: 204-210.
3. Anderson IM,. 1998. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 7: S1-S11.
4. Arias B, Catalán R, Gasto C, Gutiérrez B, Fananas L,. 2003. 5-HTTLPR polymorphism of the serotonin transporter gene predicts nonremission in major depression patients treated with citalopram in a 12-week follow-up study. J Clin Psychopharmacol 23: 563-567.
5. Arias B, Serretti A, Lorenzi C, Gastó C, Catalán R, Fañanás L,. 2006. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J Affect Disord 90: 2-3.
6. Austin MP, Mitchell PM, Goodwin GM,. 2001. Cognitive deficits in depression. Br J Psychiatry 178: 200-206.
7. Bagby RM, Ryder AG, Cristi C,. 2002. Psychosocial and clinical predictors of response to pharmacotherapy for depression. J Psychiatry Neurosci 27: 250-257.
8. Battista-Cassano G, Puca F, Scapicchio PL, TrabucchI M, the Italian Study Group on Depression in Elderly Patients. 2002. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. J Clin Psychiatry 63: 396-402.
9. Benedetti F, Colombo C, Pirovano A, Marino E, Smeraldi E,. 2009. The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology 203: 155-160.
10. Berrettini W, 2002. Psychiatric pharmacogenetics: a developing science. Neuropsychopharmacology 26: 128-129.
11. Constant EL, Adam S, Gillain B, Seron X, Bruyer R, Seghers A,. 2005. Effects of sertraline on depressive symptoms and attentional and executive functions in major depression. Depress Anxiety 21: 78-89.
12. Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D,. 2002. Achieving remission with venlafaxine and fluoxetine in major depression. Its relationship to anxiety symptoms. Depress Anxiety 16: 4-13.
13. Deutsch AY, Roth RH,. 1999. Neurotransmiters. In Fundamental Neuroscience, Zigmon FJ, Bloom FE, Landis SC, Roberts JL, Squire LR, (eds). Academic Press: San Diego; 193-234.
14. Dunkin JJ, Leuchter AF, Cook IA, Kasl-Godley JE, Abrams M, Rosenberg-Thompson S,. 2000. Executive dysfunction predicts nonresponse to fluoxetine in major depression. J Affect Disord 60: 13-23.
15. Egan MF, Goldberg TE, Kolachana BS, et al,. 2001. Effect of COMT val198/158met genotype on frontal lobe function and risk of schizophrenia. Proc Natl Acad Sci USA 98: 6917-6922.
16. Egeland J, Rund BO, Sundet K, Landro NI, Asbjornsen A, Lund A,. 2003. Attention profile in schizophrenia compared with depression: differential effects of processing speed, selective attention and vigilance. Acta Psychiatr Scand 108: 276-284.
17. Fava M, Rush AJ, Alpert JE,. 2008. Difference in treatment outcome in outpatients with anxious depression versus non-anxious depression. A STAR*D report. Am J Psychiatry 165: 342-351.
18. Fergusson JM, Wesnes KA, Schwartz GE,. 2003. Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol 18: 9-14.
19. Gartlehner G, Gaynes BN, Hansen RA, et al,. 2008. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 149: 734-750.
20. Gordovil A, Guàrdia J, Peró M,. 2012. Estimation of logistic regression models in small samples. A simulation study using a weakly informative default prior distribution. Psicológica 33: 319-335.
21. Gualtieri TC, Johnson LG, Benedict KB,. 2006. Neurocognition in depression: patients on and off medication versus healthy comparison subjects. J Neuropsychiatry Clin Neurosci 18: 217-225.
22. Gudayol-Ferré E, Herrera-Guzmán I, Camarena B, et al,. 2010. The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder. J Affect Disord 127: 343-351.
23. Hamilton M,. 1967. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 4: 278-296.
24. Heils A, Teufel A, Petri S, et al,. 1996. Allelic variation of human serotonin transporter gene expression. J Neurochem 66: 2621-2624.
25. Herrera-Guzmán I, Gudayol-Ferré E, Lira-Mandujano J, et al,. 2008. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder. Psychiatry Res 160: 72-82.
26. Herrera-Guzmán I, Gudayol-Ferré E, Herrera-Guzmán D, Guàrdia-Olmos J, Hinojosa-Calvo E, Herrera-Abarca JE,. 2009. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J Psychiatr Res 43: 855-863.
27. Herrera-Guzmán I, Gudayol-Ferré E, Herrera-Abarca J, et al,. 2010a. Major depressive disorder in recovery and neuropsychological functioning: the effects of SSRI and SNRI on residual cognitive deficits in patients with major depressive disorder in recovery. J Affect Disord 123: 341-350.
28. Herrera-Guzmán I, Herrera-Abarca JE, Gudayol-Ferré E, et al,. 2010b. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder. Psychiatry Res 177: 323-329.
29. Hosmer DW, Lesmeshow S,. 1981. Applied Logistic Regression. Wiley & Sons: New York.
30. Hu X, Oroszi G, Chum J, Smith TL, Goldman D, Schucki MA,. 2005. An expanded evaluation of the relationship of four alleles to the level of response to alcohol and the alcoholism risk. Alcohol Clin Exp Res 29: 3-16.
31. Hu XZ, Rush AJ, Charney D, et al,. 2007. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 64: 783-792.
32. Ito K, Yoshida K, Sato K, et al,. 2002. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res 111: 235-239.
33. Joyce PR, Paykel ES,. 1989. Predictors of drug response in depression. Arch Gen Psychiatry 46: 89-99.
34. Kampf-Sherf O, Zlotogorski Z, Gilboa A, et al,. 2004. Neuropsychological functioning in major depression and responsiveness to selective serotonin reuptake inhibitors antidepressants. J Affect Disord 82: 453-459.
35. Kato M, Serretti A,. 2010. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 15: 473-500.
36. Keller MB,. 2004. Remission versus response: the new gold standard of antidepressant care. J Clin Psychiatry 65 (Suppl 4): 53-59
37. Kemp AH, Gordon E, Rush J, Leanne M, Williams M,. 2008. Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging and genetic measures. CNS Spectr 13: 1066-1086.
38. Kim DK, Lim SW, Lee S, et al,. 2000. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 11: 215-219.
39. Kraft JB, Peters EJ, Slager SL, et al,. 2007. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry 61: 734-742.
40. Lesch KP, Bengel D, Helis A, et al,. 1996. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274: 1527-1531.
41. Lezak MD, Howiesson DB, Loring DW,. 2004. Neuropsychological Assessment, 4th edn. Oxford University Press: Oxford.
42. MacQueen GM, Galway TM, Hay J, Young LT, Joffe RT,. 2002. Recollection memory deficits in patients with major depressive disorder predicted by past depressions but not current mood state or treatment status. Psychol Med 32: 251-258.
43. McMahon FJ, Buervenich S, Charney D, et al,. 2006. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 78: 804-814.
44. Porter RJ, Gallagher P, Thompson JM, Young AH,. 2003. Neurocognitive impairment in drug-free patients with major depressive disorder. Br J Psychiatry 182: 214-220.
45. Potter GG, Kittinger JD, Wagner HR, Steffens DC, Krishnan KR,. 2004. Prefrontal neuropsychological predictors of treatment remission in late-life depression. Neuropsychopharmacology 29: 2266-2271.
46. Robbins TW, James M, Owen AM, Sahakian BJ, McIness L, Rabitt P,. 1994. Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia 5: 266-281.
47. Rogers MA, Kasai K, Matsuo K, et al,. 2004. Executive and prefrontal dysfunction in unipolar depression: a review of neuropsychological and imaging evidence. Neurosci Res 50: 1-11.
48. Rush AJ, Trivedi MH, Wisniewski SR, et al,. 2006. Bupropion-SR, sertraline or venlafaxine XR after failure of SSRI's for depression. N Engl J Med 354: 1231-1242.
49. Sheehan DV, Lecrubier Y, Sheehan KH, et al,. 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Clin Psychiatry 59 (Suppl 20): 22-33.
50. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Pérez J, Catalano M,. 1998. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 3: 508-511.
51. Spronk D, Arns M, Barnett KJ, Cooper NJ, Gordon E,. 2011. An investigation of EEG, genetic and cognitive markers of treatment response to antidepressant medication in patients with major depressive disorder: a pilot study. J Affect Disord 128: 41-48.
52. Stahl, 2002. Psicofarmacología Esencial. Ed. Ariel: Madrid.
53. Szegedi A, Rujescu D, Tadic A, et al,. 2005. The catechol-O- methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J 5: 49-53.
54. Taylor BP, Bruder GE, Stewart JW, et al,. 2006. Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients. Am J Psychiatry 163: 73-78.
55. Tsai SJ, Gau YT, Hong CJ, Liou YJ, Yu YW, Chen TJ,. 2009. Sexually dimorphic effect of catecol-O-methyltransferase val 158 met polymorphism on clinical response to fluoxetine in major depressive patients. J Affect Disord 113: 183-187.
56. Vallejo-Ruiloba J, Leal-Cercós C,. 2005. Tratado de Psiquiatría. Ed. Ars Médica: Barcelona.
57. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR,. 2007. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep 6: 449-459.
58. Weiland-Fielder P, Erickson K, Waldeck T, et al,. 2004. Evidence for continuing neuropsychological impairments in depression. J Affect Disord 82: 253-258.
59. Westheide J, Wagner M, Quednow B, et al,. 2007. Neuropsychological performance in partly remitted unipolar depressive patients: focus on executive functioning. Eur Arch Psychiatry Clin Neurosci 257: 389-395.
60. Yoshida K, Naito S, Takahashi H, et al,. 2002. Monoamine oxidase: a genepolymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 7-8: 1279-1283.
61. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ,. 2002. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 7: 1115-1119.
62. Zakzanis KK, Leach T, Kaplan E,. 1998. On the nature and pattern of neurocognitive function in major depressive disorder. Neuropsychiatry Neuropsychol Behav Neurol 11: 111-119.
63. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E,. 2000. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 20: 105-107.
64. Zobel A, Maier W,. 2010. Pharmacogenetics of antidepressive treatment. Eur Arch Psychiatry Clin Neurosci 260: 407-417.